Cellular and Molecular Life Sciences CMLS

, Volume 61, Issue 23, pp 2939–2953

Oncogenic protein tyrosine kinases

The emerging normal and disease-related roles of anaplastic lymphoma kinase
  • K. Pulford
  • L. Lamant
  • E. Espinos
  • Q. Jiang
  • L. Xue
  • F. Turturro
  • G. Delsol
  • S. W. Morris
Multi-author Review

DOI: 10.1007/s00018-004-4275-9

Cite this article as:
Pulford, K., Lamant, L., Espinos, E. et al. CMLS, Cell. Mol. Life Sci. (2004) 61: 2939. doi:10.1007/s00018-004-4275-9

Abstract.

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase, the normal role of which remains to be completely elucidated. Although work carried out in mammals suggests a function in neural development, results from studies in Drosophila indicate an additional role in visceral muscle differentiation. The aberrant expression of full-length ALK receptor proteins has been reported in neuroblastomas and glioblastomas, while the occurrence of ALK fusion proteins in anaplastic large cell lymphoma (ALCL) has resulted in the identification of the new tumor entity, ALK-positive ALCL. ALK represents one of few examples of a receptor tyrosine kinase implicated in oncogenesis in both haematopoietic and non-haematopoietic tumors, given that ALK fusions also occur in the mesenchymal tumor known as inflammatory myofibroblastic tumor (IMT). The study of ALK fusion proteins, besides demonstrating their importance in tumor development, has also raised the possibility of new therapeutic treatments for patients with ALK-positive malignancies.

Key words.

ALK NPM-ALK ALCL IMT lymphoma receptor tyrosine kinase 

Copyright information

© Birkhäuser Verlag, Basel 2004

Authors and Affiliations

  • K. Pulford
    • 1
  • L. Lamant
    • 2
  • E. Espinos
    • 2
  • Q. Jiang
    • 3
  • L. Xue
    • 3
  • F. Turturro
    • 4
  • G. Delsol
    • 2
  • S. W. Morris
    • 3
  1. 1.Nuffield Department, Clinical Laboratory Sciences, John Radcliffe HospitalLeukaemia Research Fund Immunodiagnostics UnitOxfordUnited Kingdom
  2. 2.Department of Oncogenesis and signalling in hematopoietic cells, Centre de Physiopathologie de Toulouse-PurpanINSERM U563ToulouseFrance
  3. 3.Departments of Pathology and Hematology-OncologySt. Jude Children’s Research HospitalMemphisUSA
  4. 4.Department of MedicineFeist-Weiller Cancer Center, LSU Health Sciences CenterShreveportUSA

Personalised recommendations